WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%.

To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...